BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAF<sup>V600E</sup> (mutant) papillary thyroid carcinoma progression and sorafenib resistance
Xing Chen, Xiang Chen, Wen Jun Xie, Hua Ge, HE Hong-yan, Ailong Zhang, Junjie Zheng
Abstract
PTC patients.
Topics & Concepts
SorafenibThyroid carcinomaCancer researchMutantMutationInternal medicineThyroid cancerMedicineOncologyThyroidHepatocellular carcinomaBiologyEndocrinologyGeneGeneticsFerroptosis and cancer prognosisCancer, Lipids, and Metabolism